BioSpace News Archive

While there are all kinds of advice out there, here are a few things NOT to do in your next interview. Make sure to avoid these interview mistakes at all costs.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Fauci said the first COVID-19 vaccines could ship late December or early January.

Burning Rock Biotech Limited announced that analytical validation data of its fully-automated NGS library preparation platform, Magnis BR, will be presented at the Association for Molecular Pathology 2020 annual meeting, in a platform presentation on Thursday, November 19, 2020.

TransMedics Group, Inc. (“TransMedics”) (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of the management team will be virtually participating in two upcoming investor conferences

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2020.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to rifaximin for the treatment of sickle cell disease

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020 . AcelRx management will host a live webcast and conference call at 4:30 p.m. Eastern Time ( 1:30 p.m. Pacific Time ) on Nov

Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2021 ended September 30, 2020.

-Net Product Sales $267.5 Million in 3Q20, an Increase of 60 Percent Over 3Q19- -Collaborations with Merck for Ladiratuzumab Vedotin and TUKYSA; Seagen Received $725M in Upfront Payments and $1B Equity Investment- -Positive Data from Two PADCEV Clinical Trials to Support Global Registration Applications and Expand U.S. Indication- -Positive Data from Tisotumab Vedotin Pivotal Trial; BLA Planned to Support U.S. Accelerated Approval-